polyclonal detection antibodies  (nanoComposix)

Journal: Chemical Science

Article Title: A (poly)Pro tip for preserving native disulfide connectivity during thiol–maleimide bioconjugation of disulfide-rich peptides

doi: 10.1039/d5sc08821f

Figure Lengend Snippet: Crystal structure of tetrameric ectodomain of LINGO-1 (left). Structure of the LINGO-1 N-cap [1–20] region, displaying a DRP motif (top right, cornflower blue). 3D NMR solution structure obtained for synthetic LINGO-1[1–20], 1 (box, bottom right, magenta).

Article Snippet: Remarkably, our polyclonal IgG detected LINGO-1 at a five-fold higher dilution than the commercial polyclonal IgG antibody AF3086 In a previous study, screening of all commercially available IgGs identified polyclonal IgG AF3086 as the most suitable for co-immunoprecipitation studies. (R&D Systems), while also yielding stronger overall staining intensity (Fig. S52 and S53).

Techniques:

Journal: Chemical Science

Article Title: A (poly)Pro tip for preserving native disulfide connectivity during thiol–maleimide bioconjugation of disulfide-rich peptides

doi: 10.1039/d5sc08821f

Figure Lengend Snippet: Synthesis of C-terminal amidated LINGO-1[1–20]-Gly-Anl 4. Reagents and conditions: [a] DMSO/H 2 O – 1 : 9, peptide conc. 0.32 mM*, 100 h, r.t.; [b] AcOH/160 mM aq. HCl – 93.6 : 6.4 containing 62.5 mM of I 2 , peptide conc. 1 mM*, 2 h, r.t. Abbreviations: Anl = 6-Azido- l -norleucine, represented in the scheme as “K(N 3 )”; DMSO = dimethyl sulfoxide; r.t. = room temperature. *Steps [a] and [b] were carried out on crude material, with concentrations calculated from the crude mass as if it corresponded to the pure compound.

Article Snippet: Remarkably, our polyclonal IgG detected LINGO-1 at a five-fold higher dilution than the commercial polyclonal IgG antibody AF3086 In a previous study, screening of all commercially available IgGs identified polyclonal IgG AF3086 as the most suitable for co-immunoprecipitation studies. (R&D Systems), while also yielding stronger overall staining intensity (Fig. S52 and S53).

Techniques:

Journal: Chemical Science

Article Title: A (poly)Pro tip for preserving native disulfide connectivity during thiol–maleimide bioconjugation of disulfide-rich peptides

doi: 10.1039/d5sc08821f

Figure Lengend Snippet: (A) ELISA cell assay showing the interaction between decreasing concentrations of polyclonal IgG and HEK cells expressing LINGO-1. Absorbance values at 450 nm were background-corrected by subtracting the signal from non-transfected HEK cells. (B) Superposition of the [1–20] region for LINGO-1-to-4 homologs shows that all Cys residues are conserved; additional conserved residues are highlighted in dark grey, whereas similar residues—defined by comparable hydrophilicity ( e.g. , Ser vs. Thr) or charge ( e.g. , Lys, Arg, or His)—are shown in light grey. (C) Western blot detail in which polyclonal IgG was used for staining HEK cells and LINGO homologs 1–4. Anti-GAPDH staining is shown at the bottom as a loading control.

Article Snippet: Remarkably, our polyclonal IgG detected LINGO-1 at a five-fold higher dilution than the commercial polyclonal IgG antibody AF3086 In a previous study, screening of all commercially available IgGs identified polyclonal IgG AF3086 as the most suitable for co-immunoprecipitation studies. (R&D Systems), while also yielding stronger overall staining intensity (Fig. S52 and S53).

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Transfection, Western Blot, Staining, Control

Journal: Journal of Inflammation Research

Article Title: Association of Increased Nasal Fluids-Serum Concordance of Protein Profile with Prognosis in Nasal Polyps

doi: 10.2147/JIR.S567454

Figure Lengend Snippet: Expression validation of LIFR in CRSwNP. ( A ) Transcriptional levels of biomarkers (LIFR, LIF, IL-5, IL-13) in PR versus non-PR groups. ELISA quantification of LIFR concentrations in both ( B ) serum and ( C ) NF of PR patients compared to non-PR and control groups. ( D ) Representative images of H&E and LIFR immunohistochemical staining (Magnification ×400). ( E ) Quantification of LIFR protein expression intensity (n=6/group). ( F and G ) scRNA-seq analysis of CRSwNP tissues showing LIFR expression patterns across cell populations (left: cell type clusters; right: LIFR expression). ( H ) Immunofluorescence of LIFR (red) co-localization with vascular endothelial cells (CD31+, green) and nuclear staining (DAPI, blue) at ×400 magnifications (n=6/group). * P < 0.05, ** P < 0.01, **** P < 0.0001.

Article Snippet: After 1 h blocking with 10% BSA at room temperature, sections were incubated overnight at 4°C with primary antibodies, including neutrophil elastase (NE; Abcam #ab68672) for neutrophil quantification or LIFR (Origene #TA386958) for LIFR expression detection, followed by DAB substrate.

Techniques: Expressing, Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Control, Immunohistochemical staining, Staining, Immunofluorescence

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet:

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Injection, Clinical Proteomics

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet: A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using mAb35, while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Saline, Injection, Clinical Proteomics, Expressing, Comparison

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet: C3 protein levels in plasma of healthy animals receiving a single treatment injection to establish the dose range of C3-siRNA for the PTMG study. After baseline measurements on day 0, C3-siRNA was administered on day 1 (black arrow) and plasma C3 protein levels analyzed on days 3, 8, 15, 22, and 29. Per group N=3. Group averages are shown.

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Clinical Proteomics, Injection

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet: C3 protein levels in plasma of healthy animals receiving three consecutive treatment injections, with a cumulative dose equal to a single injection as shown in . After baseline measurements on day 0, C3-siRNA was administered on day 1, 2, and 3 (black arrows) and plasma C3 protein levels analyzed on day 3, 8, 15, 22 and 29. Per group N=3. Group averages are shown.

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Clinical Proteomics, Injection

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet: Three days after treatment injection, hepatic C3 mRNA expression was significantly repressed in all C3-siRNA treated animals (left). 30 days after C3-siRNA injection, the expression was still reduced to 50% and ca. 25% in animals that received 10 or 30 mg/kg C3-siRNA (single and cumulative) compared to control animals. Each dot indicates one animal. Statistical analysis as performed using One-Way ANOVA with post-hoc Bonferroni’s multiple comparison test; α=0.05; **p=0.003, ***p<0.0004, ****p<0.0001.

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Injection, Expressing, Control, Comparison

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet: One PTMG animal treated with 30 mg/kg C3-siRNA showed no siRNA in the liver. Assuming a misinjection of C3-siRNA, this animal was excluded from the analysis. Each dot indicates one animal. Statistical analysis was performed using One-Way ANOVA with post-hoc Bonferroni’s multiple comparison test; α=0.05; ***p=0.0009, ****p<0.0001.

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Comparison

Journal: bioRxiv

Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

doi: 10.1101/2025.08.31.673367

Figure Lengend Snippet: A) Grip strength decreased in PTMG animals after disease induction (red arrow) with a dose-dependent effect of the C3-siRNA treatment. B) Grip strength on day 17 with non-MG animals pooled into one group. C) Disease scoring increased in PTMG animals after disease induction (red arrow), with an evident dose dependent effect of the C3-siRNA treatment. D) Disease score on day 17 with non-MG animals pooled into one group. In A) and C) group averages are shown. In B) and D) each dot represents one individual animal; horizontal bars indicate group means. Statistical analysis was performed with Two-Way ANOVA (A-C), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (B) or Kruskal-Wallis test (D); α=0.05; *p=0.0408, **p=0.0021, ****p<0.0001.

Article Snippet: Next, plates were again washed and 25 μl/well of primary detection goat anti-C3-Biotin antibody ( :1000 in 1% Blocker A buffer, Origene #AP21439BT-N) was added and incubated for 1 h at RT with shaking.

Techniques: Comparison